<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586976</url>
  </required_header>
  <id_info>
    <org_study_id>1107-05</org_study_id>
    <secondary_id>Contract number 1a5777</secondary_id>
    <nct_id>NCT00586976</nct_id>
  </id_info>
  <brief_title>A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery</brief_title>
  <official_title>A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Nordic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac surgery is associated with pain in the post-operative period. We plan to conduct a&#xD;
      study of local anesthetic, ropivacaine, infusion into the sternal wound in adult patients&#xD;
      undergoing cardiac surgery to see if it will be safe and result in improved pain control and&#xD;
      reduced time to extubation, duration of ICU and hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Cardiac surgery is associated with pain in the post-operative period. Recently the ability to&#xD;
      infuse local anesthetic drugs into the area of the sternal wound has become available. The&#xD;
      studies that have been done thus far have shown efficacy in controlling pain but have been&#xD;
      too small to show clinically significant patient outcome differences.&#xD;
&#xD;
      Specific Aim:&#xD;
&#xD;
      We plan to conduct a phase II/III study of local anesthetic infusion into the sternal wound&#xD;
      in adult patients undergoing cardiac surgery.&#xD;
&#xD;
      In the Phase II study, 40 patients will be enrolled in a prospective observational open&#xD;
      label, dose escalation study of safety and efficacy of local anesthetic infusion into the&#xD;
      sternal wound. Outcome measures for efficacy will be visual analog pain (VAP) scores and&#xD;
      opioid consumption. Outcome measures for safety will be plasma ropivacaine concentrations and&#xD;
      adverse events.&#xD;
&#xD;
      The dose determined in the phase II study will be used in the Phase III study. In this study,&#xD;
      200 patients will be enrolled in a double blind prospective, randomized, double blind;&#xD;
      placebo controlled trial of local anesthetic infusion into the sternal wound. Outcome&#xD;
      measures for efficacy will be visual analog pain (VAP) scores, opioid consumption, time to&#xD;
      extubation, pulmonary function tests, duration of ICU and hospital stay, all cause morbidity&#xD;
      and mortality. Outcome measure for safety will be adverse events.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Local anesthetic infusion into the sternal wound will be safe and result in improved pain&#xD;
      control and reduced time to extubation, duration of ICU and hospital stay.&#xD;
&#xD;
      Significance:&#xD;
&#xD;
      This will be the first large randomized controlled clinical trial assessing outcomes with the&#xD;
      use of local anesthetic infusion into the sternal wound in patients undergoing open-heart&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped by DSMB due to increased wound infection rate.&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog pain</measure>
    <time_frame>64 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>drug toxicity</measure>
    <time_frame>64 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection</measure>
    <time_frame>64 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>narcotic usage</measure>
    <time_frame>64 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivicaine infusion into the sternal wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline infusion into the sternal wound</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>0.3% ropivacaine infusion at 4 ml/hr for 64 hours.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline infusion at 4 ml/hour for 64 hours.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be greater than 18 years of age&#xD;
&#xD;
          2. Be undergoing a cardiac surgical procedure via median sternotomy (i.e., exclude the&#xD;
             occasional thoracotomy, since much greater pain with that surgical approach&#xD;
             post-operatively)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are unable to grant informed consent or comply with study procedure&#xD;
&#xD;
          2. Are undergoing emergency open heart-surgery&#xD;
&#xD;
          3. Allergic to any of the excipients in ropivacaine, propofol, and fentanyl&#xD;
&#xD;
          4. Age &lt; 18 years of age (children have dosing and toxicity concerns)&#xD;
&#xD;
          5. Are pregnant (pregnancy changes pain thresholds)&#xD;
&#xD;
          6. Taking preoperative opioids. (Opioid tolerant patients will require significantly more&#xD;
             post-operative opioid use.)&#xD;
&#xD;
          7. Cirrhosis or hepatic failure (may have accumulation of local anesthetic in plasma due&#xD;
             to decreased metabolism)&#xD;
&#xD;
          8. Patient receiving lidocaine infusion prior to surgery. (An extremely rare event)&#xD;
&#xD;
          9. Patients having a planned circulatory arrest for their surgical procedure (increased&#xD;
             duration of intubation possible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A. Nuttall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <name_title>Gregory A. Nuttall</name_title>
    <organization>Mayo Clinic College of Medicine</organization>
  </responsible_party>
  <keyword>pain, ropivacaine, infusion, sternotomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

